Antibacterial drug discovery guided by Artificial Intelligence

Principal Investigator: Yves Brun
Theme : Artificial Intelligence (AI) / Health
Competition : Genomics Integration Program - Human Health
Status : In progress
Start : July 1, 2021
End: June 30, 2023
Budget : $400,000.00

With rising antibiotic resistance and declining investment in drug development, the world faces an urgent need for new drugs to fight bacterial infection. Our goal is the efficient development of new and highly effective antibacterial drugs to expand available treatment options. We will screen thousands of chemicals for their effects on bacteria, using high-resolution microscopy to measure in detail their impact on bacterial cells. Similarly, by selectively interfering with each gene in the bacterial genome, we will observe the effects of disturbing various potential drug targets. Using these data and cutting-edge artificial intelligence techniques, we will identify antibacterial drug candidates from among millions of previously untested chemicals, even those never synthesized. Furthermore, our strategy will allow prediction of drugs acting on targets not exploited by previous generations of antibiotics, offering great potential in reducing or eliminating the emergence of resistant bacteria.


Lead Genome Centre: Génome Québec


User : 

Sébastien Giguère InVivo AI